newwin
Luciann Nguyen
Settings
← Accounts
academic

Shanghai Chest Hospital

59
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Shanghai Chest Hospital

New trial — Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

New trialNCT06456138
59/100
Opportunity
Commercial fit12/25
Clinical timing20/20
Biomarker need10/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5

New phase 1_2 trial NCT06456138 posted by Shanghai Chest Hospital: "Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC". New trial on a phase 1_2 not yet recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 817 days ago.

ConfidenceHigh · 95%clinical development · translational medicine · clinical operations
Draft outreachReview

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.

Trials

TrialPhaseTesting language
NCT06456138
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
phase 1 2
mol. elig.